GMP approved factory,stable supplying, competitive price
*The following content is generated by AI and is for reference only.
Favipiravir, chemically known as 6-fluoro-3-hydroxy-2-pyrazinecarboxamide, is a novel antiviral agent primarily utilized for the treatment of influenza. Its molecular formula is C5H4FN3O2, and it holds the CAS registry number 108977-39-5. Originally developed by Toyama Chemical in Japan, this small molecule functions as a broad-spectrum RNA-dependent RNA polymerase inhibitor. Unlike many conventional antivirals that target specific viral proteins, Favipiravir mimics purine nucleosides, thereby integrating into the growing viral RNA chain. This integration triggers lethal mutagenesis, effectively halting viral replication through the accumulation of mutations that render the virus non-viable.
The drug has gained significant global attention, particularly during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, where it was investigated as a potential therapeutic option alongside its established use against influenza A and B viruses. It is approved for emergency use or full marketing authorization in several countries, including China, Russia, and India, for treating novel viral infections. The administration of Favipiravir is typically oral, offering a convenient route compared to intravenous therapies. Clinical studies have suggested efficacy in reducing viral load and shortening the duration of symptoms when administered early in the course of infection. However, its safety profile requires careful monitoring, especially regarding potential teratogenic effects, which necessitates strict contraindications for pregnant women. While not a panacea, Favipiravir represents a critical tool in the antiviral arsenal due to its unique mechanism of action and ability to combat rapidly mutating RNA viruses. Ongoing research continues to explore its potential applications against other emerging viral threats, solidifying its role in modern infectious disease management strategies worldwide.